• Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 386,240 common shares on July 2, 2026.
• Sales priced at USD 21.74 to USD 22.45 per share.
• Directly owned stake fell to 1,019,658 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001780851-26-000015), on July 07, 2026, and is solely responsible for the information contained therein.